BRIEF-Bristol-Myers says EMA validates type II variation application for Opdivo
September 20, 2016 at 08:17 AM EDT
* European Medicines Agency validates Bristol Myers Squibb's type II variation application for Opdivo (nivolumab) in advanced form of bladder cancer